SR
SRRK.US Scholar Rock Holding Corp
- Market cap
- USD 5.50B
- P/E
- -
- P/B
- 32.21x
- ROE
- -255.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SRRK.US undervalued?
Graham numberThe Graham number of Scholar Rock Holding Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Scholar Rock Holding Corp fundamental analysis
No fundamental analysis for Scholar Rock Holding Corp yet.
Scholar Rock Holding Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal…
Full company profileScholar Rock Holding Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Scholar Rock Holding Corp annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 379K | 0.00 | 0.00 | 20.5M | 15.4M | 18.8M | 33.2M | 0.00 | 0.00 | 0.00 | 760K |
| Gross Profit | -12.1M | -669K | -36.3M | 20.5M | 15.4M | -89.7M | 33.2M | -2.84M | -1.94M | -208M | -93.3K |
| Operating Income | -16.2M | -25.0M | -50.7M | -54.5M | -86.9M | -130M | -134M | -171M | -252M | -385M | -423M |
| EBITDA | -15.6M | -24.4M | -49.9M | -53.2M | -85.4M | -129M | -131M | -163M | -238M | -369M | -414M |
| Net Income | -16.2M | -25.0M | -49.3M | -49.7M | -85.0M | -132M | -132M | -166M | -246M | -378M | -430M |
| EPS | -0.91 | -1.40 | -3.15 | -1.80 | -2.77 | -3.59 | -2.21 | -2.18 | -2.47 | -3.29 | -3.25 |
| Balance Sheet | |||||||||||
| Total Assets | 32.8M | 61.6M | 181M | 196M | 388M | 304M | 358M | 311M | 475M | 404M | 446M |
| Total Liabilities | 62.8M | 115M | 74.7M | 83.5M | 128M | 132M | 97.9M | 85.8M | 106M | 159M | 277M |
| Shareholders' Equity | -30.0M | -53.5M | 107M | 113M | 261M | 172M | 260M | 225M | 369M | 245M | 169M |
| Cash & Short-term Investments | 28.0M | 58.0M | 176M | 157M | 341M | 253M | 315M | 280M | 437M | 368M | 414M |
| Total Debt | 1.67M | 1.04M | 462K | 5.30M | 57.1M | 84.5M | 69.4M | 61.8M | 65.1M | 109M | 203M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -15.1M | -21.7M | 24.6M | -63.1M | -60.3M | -127M | -133M | -145M | -201M | -300M | -311M |
| Capital Expenditure | 794K | 361K | 1.49M | 3.12M | 4.09M | 5.25M | 1.06M | 71.0K | 98.0K | 602K | 227K |
| Free Cash Flow | -15.9M | -22.1M | 23.1M | -66.2M | -64.4M | -132M | -134M | -145M | -201M | -301M | -312M |
| Ratios | |||||||||||
| ROE | - | - | -46.3% | -44.0% | -32.6% | -76.6% | -50.6% | -73.6% | -66.8% | -154.0% | -255.0% |
| ROA | -49.4% | -40.6% | -27.2% | -25.3% | -21.9% | -43.3% | -36.8% | -53.3% | -51.9% | -93.5% | -96.5% |
| Net Profit Margin | -4,276.3% | - | - | -242.5% | -551.8% | -700.5% | -396.6% | - | - | - | -56,604.4% |
| Debt to Equity | - | - | 0.00x | 0.05x | 0.22x | 0.49x | 0.27x | 0.27x | 0.18x | 0.44x | 1.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Scholar Rock Holding Corp dividends
Scholar Rock Holding Corp has not paid dividends in the last 9 fiscal years.
Who owns Scholar Rock Holding Corp
- Insiders 0.73%
- Institutions 99.27%
- Public & others 0.00%
- Shares outstanding 122M
- Free float 104M
Top funds holding SRRK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard Health Care Inv | 4.99M | 4.09% | +43.84% | Sep 2026 |
| Fidelity Growth Company Fund | 4.53M | 3.72% | +0.51% | Aug 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.45M | 2.83% | +0.31% | Sep 2026 |
| MFS Mid Cap Growth A | 2.89M | 2.37% | +12.92% | Sep 2026 |
| iShares Russell 2000 ETF | 2.84M | 2.33% | 0.00% | Oct 2026 |
| State Street® SPDR® S&P® Biotech ETF | 1.96M | 1.60% | +2.68% | Oct 2026 |
| T. Rowe Price New Horizons | 1.86M | 1.53% | -11.03% | Sep 2026 |
| Polar Capital Biotech S Inc | 1.78M | 1.46% | 0.00% | Sep 2026 |
| Fidelity Select Biotechnology | 1.65M | 1.35% | 0.00% | Aug 2026 |
| Eventide Gilead N | 1.46M | 1.20% | 0.00% | Jun 2026 |
| Fidelity Growth Company K6 | 1.28M | 1.05% | +0.47% | Aug 2026 |
| Vanguard Small Cap Index | 1.23M | 1.01% | 0.00% | Sep 2026 |
| Fidelity Small Cap Index | 1.22M | 1.00% | +0.16% | Aug 2026 |
| Orbis Global Equity Investor | 1.20M | 0.98% | +45.74% | Jun 2026 |
| American Funds SMALLCAP World A | 1.13M | 0.93% | 0.00% | Sep 2026 |
| Fidelity Series Growth Company | 1.11M | 0.91% | +1.20% | Aug 2026 |
| Hood River Small-Cap Growth Instl | 1.07M | 0.88% | 0.00% | Jun 2026 |
| T. Rowe Price Integrated US Sm Gr Eq | 1.02M | 0.84% | -8.04% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 987K | 0.81% | -0.38% | Oct 2026 |
| Fidelity OTC | 943K | 0.77% | 0.00% | Aug 2026 |
Top institutions holding SRRK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| FMR Inc | 18.0M | 14.76% | +4.36% | Jun 2026 |
| Siren, L.L.C. | 9.58M | 7.85% | -11.55% | Jun 2026 |
| BlackRock Inc | 9.49M | 7.79% | +27.11% | Jun 2026 |
| Samsara BioCapital, LLC | 6.90M | 5.66% | 0.00% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 6.79M | 5.57% | +9.48% | Jun 2026 |
| Wellington Management Company LLP | 6.73M | 5.52% | +0.14% | Jun 2026 |
| Orbis Allan Gray Ltd | 5.93M | 4.87% | +41.95% | Jun 2026 |
| Vanguard Capital Management, LLC | 4.77M | 3.91% | +22.53% | Jun 2026 |
| State Street Corp | 4.73M | 3.88% | +17.30% | Jun 2026 |
| Redmile Group, LLC | 4.31M | 3.54% | -52.45% | Jun 2026 |
| NORGES BANK | 2.77M | 2.27% | +33.20% | Jun 2026 |
| Geode Capital Management, LLC | 2.75M | 2.26% | +28.14% | Jun 2026 |
| Massachusetts Financial Services Company | 2.61M | 2.14% | 0.00% | Jun 2026 |
| Bellevue Group AG | 2.45M | 2.01% | -31.66% | Jun 2026 |
| Jennison Associates LLC | 2.36M | 1.93% | -29.39% | Jun 2026 |
| Jupiter Topco LLC | 2.24M | 1.84% | 0.00% | Jun 2026 |
| Hood River Capital Management LLC | 2.22M | 1.82% | +8.54% | Jun 2026 |
| Driehaus Capital Management LLC | 2.21M | 1.81% | +14.86% | Jun 2026 |
| Eventide Asset Management, LLC | 2.11M | 1.73% | -3.91% | Jun 2026 |
| Polar Capital Holdings PLC | 1.88M | 1.54% | -5.30% | Jun 2026 |
Scholar Rock Holding Corp company profile
- Company name
- Scholar Rock Holding Corp
- Ticker
- SRRK.US
- Exchange
- USA Stocks
- Listed since
- May 24, 2018
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 289
- Fiscal year end
- December
- Address
- 301 Binney Street, Cambridge, MA, United States, 02142
- Phone
- 857 259 3860
- Website
- scholarrock.com
About Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corp management
10- Mr. David L. HallalCEO & Chairman of the Board · born 1966
- Mr. Vikas Sinha C.A., CPA, M.B.A.CFO & Treasurer · born 1963
- Mr. Robert Keith WoodsChief Operating Officer · born 1968
- Dr. Akshay Krishnadas Vaishnaw M.D., Ph.D.President of R&D, Member of Scientific Advisory Board and Director · born 1963
- Ms. Erin Moore CPAInterim Principal Financial & Accounting Officer · born 1975
- Ms. Lisa Wyman M.S.Chief Technical & Quality Officer · born 1978
- Mr. Mo Qatanani Ph.D.Chief Scientific Officer · born 1973
- Ms. Rushmie NofsingerVice President of Corporate Affairs & Investor Relations
- Ms. Junlin Ho J.D.General Counsel & Corporate Secretary · born 1979
- Ms. Caryn ParlavecchioChief Human Resources Officer · born 1972